Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CADI-R501 is a discovery-stage oncology research program developed by Bio-Modeling Systems (BMSystems) using its proprietary Computer Assisted Deductive Integration (CADI™) platform. The program utilizes mechanistic systems biology to model complex biological networks, specifically focusing on the regulation of the cell cycle and apoptosis in solid tumors. By integrating heterogeneous biological data, CADI-R501 aims to identify novel therapeutic strategies, which may include the nomination of new drug targets or the development of synergistic multi-target therapeutic protocols involving repurposed agents. As a discovery-phase initiative, the program represents the early application of heuristic modeling to predict effective interventions before the selection of a specific lead clinical candidate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CADI-R501.